A notable limitation of prospective cohort studies is that they are typically underpowered to investigate associations with clinically diagnosed neurodevelopmental disorder due to the rarity of these disorders, leading to insufficient sample size.
Reasons for the inconsistent findings are difficult to pinpoint, but it is notable that our prospective study shares marked similarities to Zhang's study [ 22] in terms of the assessment of NSAID use, where histories of medications were obtained through questions about an extensive list of major indications, and then detailed information for each episode of use was recorded.
These limitations are balanced by some notable strengths of this prospective investigation including the relatively large and well-defined study cohort with repeated laboratory measures for up to 9 years of follow-up.
We cite a number of advantages of cohort studies over case control studies for investigating environmental toxicant exposures and neurodevelopment, however a notable limitation of the prospective cohort design is loss to follow-up.
Our study has several notable strengths such as the prospective design with long follow-up, a larger number of nulliparous women compared with previous studies, and the comprehensive assessment of hormonal risk factors.
A notable example is the conjoint prospective randomized study reported by Ang et al (1999) where a concomitant boost regimen (63 Gy in 5 weeks) was compared with CF to the same total dose but given over 7 weeks.
Our prospective study produced four notable findings.
The Summa is notable for being a unique analysis of prospective social, cybernetic, and biological advances.
Notable strengths of our study include its prospective design, a large number of deaths from specific causes, a high follow-up rate, and detailed information on potentially confounding factors.
The most notable of these was a 5-year, prospective study from Oslo, Norway [ 19].
